Literature DB >> 32540634

A randomized, double blind, placebo controlled study to evaluate the effects of ashwagandha (Withania somnifera) extract on sleep quality in healthy adults.

Abhijit Deshpande1, Nushafreen Irani2, Ratna Balkrishnan2, Irin Rosanna Benny3.   

Abstract

OBJECTIVE: Non-restorative sleep (NRS) affects 10% people worldwide, leading to poor sleep quality, as well as physical and cognitive fatigue. This is the first human study in which an extract of ashwagandha (Withania somnifera Dunal L.) was evaluated for effects in improving overall sleep quality in subjects with NRS.
METHODS: In this randomized, double-blind, placebo-controlled trial, 150 healthy subjects scoring high on non-restorative sleep measures were given 120 mg of standardized ashwagandha extract (Shoden®) once daily for six weeks. Subjects were evaluated using the Restorative Sleep Questionnaire-weekly version and World Health Organization Quality of Life-Bref (WHOQOL) scale. Sleep actigraphy was used to measure the onset of sleep latency, sleep efficiency, total sleep time and wake after sleep onset. Safety of the treatment was determined by testing of vitals, hematology, biochemistry and urinalysis.
RESULTS: A total of 144 subjects completed the study, with no dropouts due to adverse events. A 72% increase in self-reported sleep quality was found for the treatment group, compared with 29% in the placebo group (p < 0.001). Based on activity monitoring data, the treatment group showed significant improvement in sleep efficiency (SE) (p < 0.01), total sleep time (p < 0.001) and sleep latency (p < 0.01) and wake after sleep onset (WASO) (p < 0.05) versus placebo after six weeks. In the ashwagandha group quality of life (QOL) scores showed significant improvement in physical (p < 0.001), psychological (p < 0.001), and environment domains (p < 0.01).
CONCLUSIONS: Supplementation with the standardized ashwagandha extract for six weeks improved the overall quality of sleep by significantly improving the NRS condition in healthy subjects. No treatment related adverse events were reported in the study. TRIAL REGISTRATION: Clinical Trials Registry-India (www.ctri.nic.in). Registration number: CTRI/2017/02/007801.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Actigraphy; Ashwagandha; Non restorative sleep; RSQ; Sleep quality

Mesh:

Substances:

Year:  2020        PMID: 32540634     DOI: 10.1016/j.sleep.2020.03.012

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  5 in total

Review 1.  The 4R's Framework of Nutritional Strategies for Post-Exercise Recovery: A Review with Emphasis on New Generation of Carbohydrates.

Authors:  Diego A Bonilla; Alexandra Pérez-Idárraga; Adrián Odriozola-Martínez; Richard B Kreider
Journal:  Int J Environ Res Public Health       Date:  2020-12-25       Impact factor: 3.390

Review 2.  Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis.

Authors:  Diego A Bonilla; Yurany Moreno; Camila Gho; Jorge L Petro; Adrián Odriozola-Martínez; Richard B Kreider
Journal:  J Funct Morphol Kinesiol       Date:  2021-02-11

Review 3.  Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa.

Authors:  Henok Kessete Afewerky; Ayeni Emmanuel Ayodeji; Bashir Bolaji Tiamiyu; Joshua Iseoluwa Orege; Emmanuel Sunday Okeke; Aanuoluwapo Opeyemi Oyejobi; Petuel Ndip Ndip Bate; Sherif Babatunde Adeyemi
Journal:  Bull Natl Res Cent       Date:  2021-10-21

4.  Withania somnifera as an Adjunctive Treatment for Refractory Restless Legs Syndrome in Parkinson's Disease: A Case Report.

Authors:  Kaustubh S Chaudhari; Rakesh R Tiwari; Saurabh S Chaudhari; Swati V Joshi; Harish B Singh
Journal:  Cureus       Date:  2021-12-28

Review 5.  Effects of Withania somnifera (Ashwagandha) on Stress and the Stress- Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia.

Authors:  Alex B Speers; Kadine A Cabey; Amala Soumyanath; Kirsten M Wright
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.